Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 82.35

-4.5%

Jan 8 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2712)	3/24/2010 2:58:04 PM
From: Jibacoa	Read Replies (1) of 3722

GENT is having another nice spike today.<g> The stock traded for a while above Friday's intraday H and the resistance at the $3 level. It was up 83.51% at its intraday H and still is up 58.24%. Volume has expanded and is already about 55x its ADV bigcharts.marketwatch.com GENT announced yesterday that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study. The PII/III, evaluated the prophylactic use of Defibrotide in pediatric stem cell transplant patients at high risk for veno-occulsive disease. The results from the study demonstrated that Defibrotide reduced the incidence of VOD in high risk pediatric patients. <g> Defibrotide's biological activity and mechanism of action were highlighted in a separate poster-presentation. As previously mentioned, GENT has been trimming its losses in the last 4Qs and revenues have increased in the last 2Qs. The ACTAY is $5 and although it has resistance from the Sep8 H at $4, with some good news the $5 level could be attainable.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next